Within Range: Demystifying Diabetes Tech for Healthcare Professionals

RADIANT Trial Results: The Impact on Type 1 Diabetes (T1D) Patients and a Glimpse into the Future of Diabetes Care

Tue, 21 Apr 2026 05:00:00 -0000

What happens when you transition type 1 diabetes (T1D) patients from multiple daily injections (MDI) to Omnipod 5 using Abbott’s Freestyle Libre 2? That is exactly what the RADIANT Randomized Controlled Trial (RCT) investigated.

Listen to Within Range with Kate Neal, Clinical Services Manager at Insulet who is joined by Dr. Emma Wilmot - Associate Professor at University of Nottingham, consultant Diabetologist, & founder of the Diabetes Technology Network UK - to unpack the incredible results of the RADIANT trial and discuss its impact on patients and the future of diabetes care.

Recently published in The Lancet Diabetes & Endocrinology journal, Dr Emma Wilmot shares not just the results of the RADIANT trial but also how she approaches onboarding her patients with Automated Insulin Delivery (AID), highlighting the importance of peer support, and how she is contributing to reducing the daily burden of those living with type 1 diabetes (t1d).

---

How can continuous glucose monitoring and tubeless insulin delivery help people living with diabetes? Within Range is a podcast for healthcare professionals (HCPs), helping them stay up to date on the latest diabetes innovations.

Within Range is presented by Kate Neal and Cindy Pickering (Clinical Services Managers at Insulet) who sit down with diabetes healthcare professionals from across the world to discuss clinical research, best practices and how Omnipod 5 Automated Insulin Delivery systems (AIDs) can help simplify diabetes management for patients with Type 1 diabetes (T1D).

If you’re looking to improve your patient’s time in range as well as time in happiness, then this is the podcast for you.

---

Disclaimer

Note: The information in this podcast is accurate to the date of recording as of 12/03/2024. Dr. Emma Wilmot’s, views and opinions expressed in this podcast are her own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety. For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country. © Insulet Corporation. All rights reserved. INS-OHS-04-2026-00067 v1.0

REPLAY: Understanding Omnipod 5: The future of Diabetes Tech

Tue, 17 Mar 2026 06:00:00 -0000

In our inaugural episode, hosts Kate Neal and Cindy Pickering are joined by Dr Sufyan Hussain, consultant in diabetes, endocrinology and general medicine at Guys and St Thomas’s Hospital in London. Dr Hussain talks about his personal and professional experience with type 1 diabetes and how he has seen technology rapidly evolve over the past decade. He discusses his work as a clinician, helping others to manage diabetes with game-changing results through Omnipod® 5 and the approach to training patients on the Omnipod® 5 System in the UK. He provides practical advice to clinicians and sets expectations for patients just starting out with the technology, and shares case studies where there has been a significant breakthrough in the management of diabetes.

Recorded in March 2024.

Disclaimer

Note: The information in this podcast is accurate to the date of recording as of 27/03/2024. Dr. Sufyan Hussain, interviewed here, received a fee from Insulet for taking part in this podcast. Views and opinions expressed in this podcast are his own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5, including indications, contraindications and important safety information for the UK, please visit: https://www.omnipod.com/en-gb/safety

For other regions, please refer to country-specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.

INS-OHS-03-2026-00187 v1.0

Clinical Data and Practical Experience: The Impact of Omnipod® 5

Tue, 17 Feb 2026 09:00:00 -0000

For people living with type 1 diabetes, simplifying daily glycaemic management is essential, and Omnipod 5 is helping people do just that.

In this episode of Within Range, host Kate Neal - Clinical Services Manager at Insulet, sits down with Dr Fraser Gibb - Consultant Physician and Diabetologist at Edinburgh Royal Infirmary and Honorary Clinical Reader at the University of Edinburgh, to explore how Omnipod 5’s intuitive technology makes diabetes care more accessible. They highlight how the device’s tubeless design and hybrid closed loop system transform diabetes management, improving outcomes.

This episode of Within Range covers:

· The simplicity of system setup, the importance of user-initiated boluses, and the personalisation of glucose targets.

· Practical strategies for initial settings and simple ways to correct high glucose levels.

· How the PANTHERTOOL® can help with pattern management and optimisation and can be accessed at https://www.omnipod.com/en-gb/hcp/education-training/panther-tool

· The role of patients in managing their diabetes effectively with technology and clinical support.

Disclaimer

Note: The information in this podcast is accurate to the date of recording as of 09/18/2025. Dr. Fraser Gibb, interviewed here, received a fee from Insulet for taking part in this Podcast, views and opinions expressed in this podcast are his own and do not necessarily reflect those of Insulet. When Dr. Gibb refers to HbA1c of 58 mmol/mol this corresponds to an HbA1c of 7.5%. When he refers to an improvement in HbA1c of 9mmol/mol this relates to an improvement of HbA1c of 0.8%. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.

INS-OHS-01-2026-00175 v2.0

Is 70% Time in Range really 70% Time in Range? Making Sense of CGM Accuracy and the impact on Automated Insulin Delivery

Wed, 07 Jan 2026 12:00:00 -0000

Automated insulin delivery (AID) relies on the accuracy of the sensor behind it—so what happens when “70% time in range” doesn’t mean the same thing across different continuous glucose monitoring (CGM) systems?

Recorded at EASD in Vienna, this special episode of Within Range brings together clinical, research and real-world perspectives to unpack how CGM accuracy, comparator methods (capillary vs venous) and standardisation efforts shape the numbers healthcare professionals rely on every day.

Registered dietitian and diabetes educator John Pemberton uses a powerful “strict vs lenient marker” analogy to explain why identical time in range figures can mask very different glucose exposure—and why pairing CGM metrics with HbA1c remains critical.

Then Insulet’s Medical Affairs team sit down with CGM experts Dr Guido Freckmann and Dr Othmar Moser to discuss new data comparing current-generation sensors (including in exercise settings), the push for unified CGM evaluation standards, implications for hybrid closed loop safety, and what health care professionals should consider when interpreting trials, real-world datasets and choosing AID systems with their patients.

Who you’ll hear from on this episode:

· Kate Neal - Clinical Services Manager at Insulet.

· Irene Hadjiyianni - Director, Medical Affairs Europe at Insulet.

· Séverine Labat – Senior Director of Medical Affairs at Insulet.

· John Pemberton – Registered dietitian and diabetes educator, sharing practical insights from supporting approximately 300 children and young people with type 1 diabetes, and how he translates sensor accuracy data into real-world AID decisions.

· Dr Guido Freckmann – Medical Director, Institute of Diabetes Technology in Germany, outlining a new challenging study procedure for CGM evaluation, key findings on sensor differences, and the drive towards clear accuracy targets.

· Dr Othmar Moser – Exercise physiology and metabolism expert, presenting data on CGM performance during physical activity, and what accuracy means for safety and trust in automated insulin delivery.

Disclaimer

Note: The information in this podcast is accurate to the date of recording as of 09/17/2025. All HCPs interviewed received a fee from Insulet for taking part in this Podcast, views and opinions of these HCPs expressed in this podcast are their own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.

Clinical data referenced in this episode can be found here:

Eichenlaub M et al. Performance of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes. J Diabetes Sci Technol. 2025 Feb 4:19322968251315459. doi: 10.1177/19322968251315459. Epub ahead of print. PMID: 39902649; PMCID: PMC11795573.

INS-OHS-11-2025-00087 v1.0

Challenging Bias: Making Diabetes Tech Accessible for Everyone

Tue, 02 Dec 2025 09:00:00 -0000

Although guidelines are pointing to Automated Insulin Delivery Systems as standard of care for managing type 1 diabetes, not all people are being offered AID as a therapy option. Why are some people still left behind—and what can healthcare professionals do about it?

In this episode of Within Range from EASD 2025 in Vienna, host Kate Neal, Clinical Services Manager at Insulet, speaks with Dr. Alice Cheng and Dr. Hood Thabit about how unconscious bias, clinical inertia, and outdated assumptions continue to shape who gets offered diabetes technology.

They discuss what happens when healthcare teams assume patients “can’t handle” diabetes tech, how automation is breaking old barriers, and the practical strategies that make access fairer—from embedding technology conversations into every visit to using group starts and peer support to reach underrepresented communities.

Who you’ll hear from on this episode:

• Dr. Alice Cheng, endocrinologist at Trillium Health Partners, University of Toronto Associate Professor, and creator of the Med Ed Pledge, sharing how simple clinic routines can dismantle unconscious bias and make technology offers equitable.

• Dr. Hood Thabit, consultant diabetologist and Senior Lecturer at Manchester University NHS Foundation Trust, explaining how outreach, empathy, and inclusive education can bring marginalized groups into automated insulin delivery programs.

Disclaimer Note: The information in this podcast is accurate to the date of recording as of 09/18/2025. All HCPs interviewed received a fee from Insulet for taking part in this Podcast, views and opinions of these HCPs expressed in this podcast are their own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/engb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.

INS-OHS-11-2025-00168 v1.0

The Origin Story of Omnipod®: Celebrating 25 Years of Innovation at Insulet

Fri, 14 Nov 2025 06:00:00 -0000

How did a sketch on a napkin during a cross-country flight spark a revolution in diabetes care? Following live discussions at the European Association for the Study of Diabetes (EASD) 2025 in Vienna, Within Range host Kate Neal introduces a special conversation led by Dominic Hulton, Vice President of International Marketing at Insulet, with John Brooks, founder of Insulet and the visionary behind tubeless insulin delivery which eventually led to the development of the Omnipod 5 Automated Insulin Delivery System.

John shares personal insights into the early days of Insulet, developing the first tubeless insulin delivery system and the impact of creating a technology that continues to empower people living with diabetes around the world. The discussion also looks ahead to the next era of innovation, exploring how advances in CGM integration, automation, and immunology could shape the future of diabetes management.

Note: The information in this podcast is accurate to the date of recording as of 09/16/2025. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.

INS-OS-10-2025-00022 v1.0

Real-world success stories about diabetes management thanks to automated insulin delivery (AID) and Omnipod® 5: Recorded at the American Diabetes Association (ADA) Conference 2025

Tue, 21 Oct 2025 04:00:00 -0000

Following live discussions with health-care providers about their experiences with Omnipod 5 at the American Diabetes Association (ADA) Conference 2025, Within Range hosts Kate Neal and Cindy Pickering reflect on how automated insulin delivery systems provide discretion and comfort, empowering patients in their diabetes care and improving outcomes after diagnosis.

We hear touching stories including one about a teenage girl finally embracing her diagnosis thanks to advancements in diabetes technology, as well as stories of children and adults improving their quality of life thanks to automated insulin delivery.

Who you’ll hear from on this episode of Within Range:

Dr DeSalvo – Paediatric endocrinologist sharing real-world success stories, focusing on easing the diabetes burden for teenagers and enhancing quality of life with Omnipod 5.
Dr Aleppo – Diabetes specialist discussing the comprehensive evidence behind offering automated insulin delivery systems to a broader range of patients, emphasising the importance of awareness and education.
Dr Zahareva – PhD and diabetes educator offering insights on optimal use of Omnipod 5 during exercise.

The experts in this episode discuss:

The challenges teenagers face in diabetes management, the impact of Omnipod 5 on improving glycemic management, and fostering healthier social relationships.
Insights from leading health-care professionals on starting patients on Omnipod 5, customising settings, and the importance of education and appropriate adjustments in system settings.
Findings from the Radiant Study highlighting transitions from multiple daily injections of insulin (MDI) to Omnipod 5, showcasing improvements in HbA1c levels and overall diabetes management.
The consensus on using automated insulin delivery systems with exercise, emphasising the role of balanced carbohydrate intake and pre-exercise system settings.

Note: The information in this podcast is accurate to the date of recording as of 06/23/2025. All HCPs interviewed received a fee from Insulet for taking part in this Podcast, views and opinions of these HCPs expressed in this podcast are their own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.

Note about some clinical claims throughout this episode:

Berget Claims: 110mg/dL Glucose Target does not increase hypoglycemia

1. Claim-000433: Forlenza G, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. Real-world data from 403 people with type 1 diabetes aged 2+ using the Omnipod 5 System who transitioned from the 150 mg/dL to 110 mg/dL Target Glucose. Each Target Glucose was used for a consecutive period of 14-90 days. Median time in Range (70-180 mg/dL) improved 11.8% (p<0.05). Median time <70 mg/dL +0.23% (p<0.05). Omnipod 5 results based on users with ≥75% of days with ≥220 readings available. Data on File. 05.15.25. RF-042025-00013

DeSalvo Claims: Adolescents improve TIR and experience less diabetes distress

2. Brown S. et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 in adults/adolescents and children = 64.7% vs. 73.9%; 52.5% vs. 68.0%. Study funded by Insulet.

3. Hood K. et al. Pediatr Diabetes (2023). Prospective pivotal trial including 42 adolescent participants with T1D aged 12-17.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Adolescents experienced reduced diabetes distress (PAID-T) 30.5 vs. 27.1 (P=0.045).

Aleppo: RADIANT improved A1c and TIR (something about hypoglycemia)

4. Claim-000498: Wilmot E, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. HbA1c 13-weeks: control group 8% vs. Omnipod 5 group 7.2% (p<0.0001). TIR 13-weeks: control group 43% vs. Omnipod 5 group 65% (p<0.0001). TBR (<70 mg/dL or 3.9mmol/L) at 13-weeks: non-inferiority was met with 2.56% TBR with Omnipod 5. Data on File. Mar 14, 2025. RF-042025-00015

Exercise Paper: Reduce meal bolus if exercising 1-2 hours after (Othmar) – reference paper here

5. Moser O, Zaharieva DP, Adolfsson P, et al. The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). Diabetologia. 2025;68(2):255-280. doi:10.1007/s00125-024-06308-z

INS-OHS-09-2025-00381 v2.0

How customisable glucose targets can individualize patient care

Tue, 02 Sep 2025 06:00:00 -0000

How to set multiple glucose target levels throughout the day and how to use customisation with Omnipod 5 to manage insulin sensitivity are what host Kate Neal - Clinical Services Manager at Insulet - talks to John Pemberton about on this episode of Within Range.

Pemberton is a renowned Paediatric Diabetes Dietitian who works to improve patient outcomes. He’s an author of the EASD/ISPAD 2024 AID and Exercise Consensus Guidance which provide comprehensive recommendations for managing physical activity in children, adolescents and young adults with diabetes.

Neal and Pemberton share insights into the practical use of Omnipod 5, when and how to customize target glucose, and various use cases for the Activity Feature beyond exercise, like nighttime adjustments.

(This episode was recorded live at Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam.)

Note: The information in this podcast is accurate to the date of recording as of 03/20/2025. John Pemberton received a fee from Insulet for taking part in this Podcast, views and opinions John expresses in this podcast are his own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.

INS-OHS-05-2025-00091 v1.0

Let’s Talk About Diabetes Tech, Intimacy, and Type 1: The Conversations We’re Not Having

Tue, 26 Aug 2025 05:01:00 -0000

In this special episode of Within Range, recorded live in Amsterdam at ATTD, host Cindy Pickering, Clinical Services Manager at Insulet, sits down with the team behind the podcast Typecast: Life Between the Lines to explore a topic that’s deeply personal, and too often overlooked in diabetes care: intimacy.

Cindy is joined by:

Natalie Balmain – Omnipod Ambassador, activist, and host of Typecast
Amanda Epps – Diabetes Specialist Nurse and researcher on diabetes tech and intimacy
Timothy Jenkinson (aka Grace Shush) – Drag artist and diabetes advocate

Together, they bring decades of lived experience with Type 1 diabetes to a raw, funny, and vital conversation. From CGMs falling off in the bedroom to confidence in dating, fear of judgment, and why healthcare professionals rarely raise the issue, this episode doesn’t shy away from the realities of managing diabetes and maintaining intimacy.

They discuss:

Why conversations around sex and diabetes tech are often absent in clinic
The emotional and physical challenges of navigating intimacy with visible tech
How gender norms and toxic masculinity affect tech use and confidence
The role of peer support and social media in filling the education gap
Simple ways HCPs can open up the conversation without fear or shame

(This episode was recorded live at Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam.)

Note: The information in this podcast is accurate to the date of recording as of 03/20/2025. Amanda Epps received a fee from Insulet for taking part in this Podcast, views and opinions Amanda expresses in this podcast are her own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.

INS-OHS-07-2025-00358 v1.0

How to empower patients by giving them a truly bespoke treatment plan

Tue, 12 Aug 2025 05:30:00 -0000

The personalisation and ease of use of Omnipod 5, its impact on improving patients' quality of life, and the Custom Foods feature that empowers users with a personalised meal library are what host Kate Neal - Clinical Services Manager at Insulet - and Dr. Eden Miller - a Family Practitioner and Diabetologist - discuss on this episode of Within Range.

Dr. Miller shares personal and poignant patient stories, bringing to light the psychological and medical barriers in accessing modern diabetes tech and how she collaborates with patients to overcome them.

In this episode of Within Range, you'll hear how beneficial the integration of technology is in diabetes management, the impact of algorithm adaptivity on patient outcomes, the importance of meeting patients at every step of the diabetes treatment journey, and the transformative role of Omnipod 5 in managing diabetes.

(This episode was recorded live at Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam.)

Note: The information in this podcast is accurate to the date of recording as of 03/20/2025. Dr. Eden Miller received a fee from Insulet for taking part in this Podcast, views and opinions Dr. Miller expresses in this podcast are her own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.

INS-OHS-05-2025-00092 v1.0

Tailored recommendations for Automated Insulin Delivery (AID) use during exercise

Tue, 01 Jul 2025 04:31:00 -0000

Introducing the Exercise Wheel and the Consensus Recommendations for managing Type 1 Diabetes during exercise are the focus of this conversation between host Kate Neal - Clinical Services Manager at Insulet - and Dr. Othmar Moser - a leading expert in exercise physiology and metabolism from the University of Bayreuth and the University of Graz.

There is new guidance developed by European Association for the Study of Diabetes (EASD) and International Society for Pediatric and Adolescent Diabetes (ISPAD), which provide evidence-based recommendations for managing glucose levels during planned and unplanned physical activities using AID Systems like Omnipod 5 – hear what they are and how they’ll impact your patients on this episode of Within Range.

Dr Moser shares strategies for insulin dosing and carbohydrate consumption to maintain optimal glycemic levels during exercise and explains how to empower patients with practical advice using the AID wheel. The wheel is a tool developed by the authors of the consensus guidance, which address patient concerns around the fear of hypoglycemia. It’s a visual way of explaining how planned and unplanned activities are going to impact glucose levels, and by giving detailed recommendations on adjusting insulin dosage, it helps HCPs and patients manage their physical activity more confidently and safely.

(This episode was recorded live at Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam.)

Note: The information in this podcast is accurate to the date of recording as of 03/20/2025. Dr. Othmar Moser received a fee from Insulet for taking part in this Podcast, views and opinions Dr. Moser expresses in this podcast are his own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.

INS-OHS-05-2025-00095 v1.0

Within Range: Demystifying Diabetes Tech Interview with Prof. Jean-Pierre Riveline

Mon, 20 Jan 2025 19:59:00 -0000

Omnipod® 5 provides impressive quality of life improvements for people living with diabetes (PWD)

Recorded at the 60th Annual EASD Scientific Meeting in Madrid, Spain, our host, Cindy Pickering, brings you a conversation with Professor Jean-Pierre Riveline. Prof. Riveline is a senior practitioner in diabetology-endocrinology at Lariboisière hospital as well as a Professor in endocrinology, and the Leader of the Centre Universitaire du Diabète et de ses Complications (CUDC), Lariboisière Hospital in Paris, France. Together Cindy and Prof. Riveline discuss revolutionary AID technology and the impressive impact that Omnipod 5 is making on both glycemia and quality of life, especially through simplicity. Some references to the Insulet Sponsored Symposium at EASD are made and for those interested in watching the recording it can be accessed via www.omnipod.com.

Note: The Podcast was recorded on September 12th 2024 and therefore content reflects information of that time. In France, Omnipod 5 is currently approved for use in patients with type 1 diabetes with HbA1c level ≥ 8% and being treated with CSII for more than 6 months and although Prof. Riveline refers to “laws changing” he meant the reimbursement scope recommended in HTA guidelines have been updated. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved, for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com Omnipod 5 may not be available in your country.

The Simplicity of Omnipod® 5 allows a wider range of people with diabetes to try Automated Insulin Delivery (AID)

Wed, 27 Nov 2024 11:29:00 -0000

Recorded at the 60th Annual EASD Scientific Meeting in Madrid, Spain, our host, Cindy Pickering, brings you a conversation with Dr. Jackie Elliott. Dr. Elliott is the clinical lead for diabetes at Sheffield Teaching Hospitals in the United Kingdom. Together Cindy and Dr. Elliott discuss revolutionary AID technology and how the simplicity of Omnipod 5 is changing clinical practice. Dr. Elliott describes some impactful case examples of how Omnipod 5 has improved outcomes for not only the person living with diabetes but has also given freedom back to the whole family. Some references to the Insulet Sponsored Symposium at EASD are made and for those interested in watching the recording it can be accessed here: [link to recording here].

Note: The information in this podcast is accurate to the date of recording as of 12th September 2024. Dr. Jackie Elliott received a fee from Insulet for taking part in this Podcast, views and opinions expressed in this podcast are her own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved, for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com Omnipod 5 may not be available in your country.

INS-OHS-11-2024-00076 v1.0

AID systems are revolutionizing paediatric diabetes care

Wed, 04 Sep 2024 09:32:00 -0000

Recorded at the ADA 84th Scientific Sessions in Orlando, Florida, host Kate Neal brings you a conversation with Cari Berget. Cari is a leading expert in diabetes and technology as a Pediatric Nurse and diabetes educator from the Barbara Davis Center in Denver, Colorado. Together Kate and Cari discuss revolutionary AID technology and the impact on pediatric patient outcomes. Cari highlights initiation and implementation strategies she uses to manage nearly 1,000 pediatric patients on Omnipod 5 and other AID systems. Cari introduces the audience to the PANTHER® Program and describes the development and use of the PANTHERTOOL®, a resource to help HCPs understand and optimize the use of diabetes technologies. For more information about the PANTHER® Program please visit https://www.pantherprogram.org/omnipod-5

Note: The information in this podcast is accurate to the date of recording as of 06/22/2024. Cari Berget received a fee from Insulet for taking part in this Podcast, views and opinions Cari expresses in this podcast are her own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com

Omnipod 5 may not be available in your country.

INS-OHS-08-2024-00159 v1.0

Hitting the target for successful glycemic management with Omnipod 5 - with Dr. Dorothee Deiss

Wed, 24 Jul 2024 16:17:00 -0000

Dr. Dorothee Deiss joins our podcast hosts Kate and Cindy to explore her work with AID systems. Dr. Deiss is a paediatric endocrinologist from Berlin, working at the DRK Clinic Berlin Westend. She says that \"every person with Type 1 Diabetes should be offered an AID system.\" Find out how you can greatly improve glycaemic control and quality of life for patients with Type 1 Diabetes. Omnipod 5 is easy to use and has an easy-to-understand algorithm that adjusts insulin delivery based on predicted glucose, 60 minutes into the future. As our hosts Kate and Cindy explore with Dr. Deiss, onboarding and follow-up care is crucial, yet simple, for the successful use of Omnipod 5 and the system works really well to manage both hyperglycaemia and hypoglycaemia for a broad patient population. To review the webinar mentioned in the episode, please click here For more information about Glooko and how to use this data management tool to support your patients on Omnipod 5, please click here Note: The information in this podcast is accurate to the date of recording as of 06/06/2024. Dr. Deiss received a fee from Insulet for taking part in this Podcast. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com Omnipod 5 may not be available in your country.

Understanding Omnipod 5: The future of Diabetes Tech

Wed, 29 May 2024 08:16:00 -0000

In our inaugural episode, hosts Kate Neal and Cindy Pickering are joined by Dr. Sufyan Hussain, consultant in diabetes, endocrinology and general medicine at Guys and St Thomas’s Hospital in London. Dr. Hussain talks about his personal and professional experience with type 1 diabetes and how he has seen technology rapidly evolve over the past decade. He discusses his work as a clinician, helping others to manage diabetes with game changing results through Omnipod® 5 and the approach to training patients on the Omnipod 5 System in the UK. He provides practical advice to clinicians and sets expectations for patients just starting out with the technology, and shares case studies where there has been a significant breakthrough in the management of diabetes.

Welcome to Within Range

Tue, 05 Mar 2024 10:10:00 -0000

Within Range is the new podcast from Insulet. Diabetes tech innovation moves quickly and it can be challenging to keep all the details about the available AID systems straight. Within Range: Demystifying Diabetes Tech will help bust some myths and clear up any confusion about the Omnipod® 5 Automated Insulin Delivery System. Our dynamic co-hosts Cindy Pickering & Kate Neal lead conversations with Healthcare Professionals with varying specialties and backgrounds. From clinical research and guidelines, system details, algorithm functionality, to the more practical aspects of helping people live with T1D, you are invited to listen in, while they cover a variety of specialisms. This professional (but entertaining) podcast aims to navigate the complexities of diabetes technology and increase understanding and confidence to help simplify diabetes management for your patients using the Omnipod 5 Automated Insulin Delivery System.